-0.03 | -0.14%
MERIDIAN BIOSCIENCE INC's gross profit margin for the second quarter of its fiscal year 2013 is essentially unchanged when compared to the same period a year ago. The company managed to grow both sales and net income at a faster pace than the average competitor in its industry this quarter as compared to the same quarter a year ago.
During the same period, stockholders' equity ("net worth") has increased by 5.39% from the same quarter last year.
| Income Statement | Q2 FY13 | Q2 FY12 |
|---|---|---|
| Net Sales ($mil) | 47.27 | 47.24 |
| EBITDA ($mil) | 0.0 | 16.43 |
| EBIT ($mil) | 15.25 | 15.03 |
| Net Income ($mil) | 10.25 | 9.63 |
| Balance Sheet | Q2 FY13 | Q2 FY12 |
|---|---|---|
| Cash & Equiv. ($mil) | 0.0 | 24.34 |
| Total Assets ($mil) | 165.99 | 158.26 |
| Total Debt ($mil) | 0.0 | 0.0 |
| Equity ($mil) | 148.35 | 140.77 |
| Profitability | Q2 FY13 | Q2 FY12 |
|---|---|---|
| Gross Profit Margin | 65.04 | 65.51 |
| EBITDA Margin | 0.0 | 34.78 |
| Operating Margin | 32.27 | 31.82 |
| Sales Turnover | 1.08 | 1.07 |
| Return on Assets | 21.62 | 18.79 |
| Return on Equity | 24.19 | 21.13 |
| Debt | Q2 FY13 | Q2 FY12 |
|---|---|---|
| Current Ratio | 0.0 | 5.65 |
| Debt/Capital | 0.0 | 0.0 |
| Interest Expense | 0.0 | 0.0 |
| Interest Coverage | 0.0 | 0.0 |
| Share Data | Q2 FY13 | Q2 FY12 |
|---|---|---|
| Shares outstanding (mil) | 41.42 | 41.26 |
| Div / share | 0.0 | 0.19 |
| EPS | 0.24 | 0.23 |
| Book value / share | 3.58 | 3.41 |
| Institutional Own % | n/a | n/a |
| Avg Daily Volume | 178131.0 | 175906.0 |
BUY. MERIDIAN BIOSCIENCE INC's P/E ratio indicates a premium compared to an average of 21.98 for the Health Care Equipment & Supplies industry and a premium compared to the S&P 500 average of 19.08. For additional comparison, its price-to-book ratio of 6.06 indicates a significant premium versus the S&P 500 average of 2.44 and a significant premium versus the industry average of 3.61. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, MERIDIAN BIOSCIENCE INC proves to trade at a premium to investment alternatives within the industry.
| Price/Earnings |
|
Price/Cash Flow |
| |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VIVO 25.23 | Peers 21.98 | VIVO NA | Peers 14.10 | |||||||||||||||||||||
|
Premium. A higher P/E ratio than its peers can signify a more expensive stock or higher growth expectations. VIVO is trading at a premium to its peers. |
Neutral. The P/CF ratio is the stock’s price divided by the sum of the company's cash flow from operations. It is useful for comparing companies with different capital requirements or financing structures. Ratio not available. |
|||||||||||||||||||||||
| Price/Projected Earnings |
|
Price to Earnings/Growth |
|
|||||||||||||||||||||
| VIVO 22.14 | Peers 21.55 | VIVO 2.02 | Peers 1.59 | |||||||||||||||||||||
|
Premium. A higher price-to-projected earnings ratio than its peers can signify a more expensive stock or higher future growth expectations. VIVO is trading at a premium to its peers. |
Premium. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples. VIVO trades at a significant premium to its peers. |
|||||||||||||||||||||||
| Price/Book |
|
Earnings Growth |
|
|||||||||||||||||||||
| VIVO 6.06 | Peers 3.61 | VIVO 19.44 | Peers -4.86 | |||||||||||||||||||||
|
Premium. A higher price-to-book ratio makes a stock less attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet. VIVO is trading at a significant premium to its peers. |
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios. VIVO is expected to have an earnings growth rate that significantly exceeds its peers. |
|||||||||||||||||||||||
| Price/Sales |
|
Sales Growth |
|
|||||||||||||||||||||
| VIVO 5.04 | Peers 6.56 | VIVO 5.77 | Peers 7.22 | |||||||||||||||||||||
|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales. VIVO is trading at a discount to its industry on this measurement. |
Lower. A sales growth rate that trails the industry implies that a company is losing market share. VIVO trails its peers on the basis of sales growth |
|||||||||||||||||||||||
